HONG
KONG, June 16, 2022 /PRNewswire/ -- Global Cord
Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing and stem cell storage services, is pleased to
announce that Cellenkos, Inc.
("CLNK") recently announced that the U.S. Food and Drug
Administration ("FDA") has cleared its Investigational New Drug
("IND") application to initiate a Phase 1b, open-label study
of CK0804 as an add on therapy to ruxolitinib in patients with
myelofibrosis who experience a suboptimal response to ruxolitinib.
Details related to this news can be found via the following
Cellenkos news announcement:
Cellenkos Receives FDA Clearance of Investigational New Drug
(IND) Application for CK0804 as Add on Therapy to Ruxolitinib for
the Treatment of Myelofibrosis (prnewswire.com)
Ms. Ting Zheng, Chief Executive Officer and Chairperson of GCBC
commented, "The Global Cord Blood team is encouraged by the above
news announced by CLNK which highlights a potentially
transformative treatment for myelofibrosis patients. We
congratulate CLNK team on this development."
About Global Cord Blood Corporation
Global Cord Blood Corporation is an umbilical cord blood banking
operator serving multiple regions in China. Global Cord Blood Corporation provides
cord blood collection, laboratory testing, hematopoietic stem cell
processing and stem cell storage services. For more information,
please visit the Company's website at:
http://www.globalcordbloodcorp.com.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com
View original
content:https://www.prnewswire.com/news-releases/global-cord-blood-corporation-announced-cellenkos-receives-fda-clearance-of-ind-application-for-ck0804-as-add-on-therapy-to-ruxolitinib-for-the-treatment-of-myelofibrosis-301569662.html
SOURCE Global Cord Blood Corporation